Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;20(6):2414-2423.
doi: 10.1111/iwj.14075. Epub 2022 Dec 30.

The use of epidermal growth factor in dermatological practice

Affiliations
Review

The use of epidermal growth factor in dermatological practice

Sun Hye Shin et al. Int Wound J. 2023 Aug.

Abstract

Epidermal growth factor (EGF) is a growth factor that plays a pivotal role in wound healing and maintaining tissue homeostasis by regulating cell survival, proliferation, migration, and differentiation. Exogenous administration of bioidentical human recombinant epidermal growth factor (rhEGF) has been known to promote skin wound healing, although rhEGF is increasingly being used in drug delivery systems and nanotechnology. However, despite considerable attention being focused on the potential clinical applications of rhEGF in several dermatological conditions beyond wound healing, the number of studies still remains relatively low. Herein, we conducted a literature search of PubMed/Medline and Google Scholar databases to retrieve published literature related to rhEGF and summarised the effects of rhEGF in the treatment of various wound types, radiotherapy or chemotherapy-related skin reactions, atopic dermatitis, skin aging, and post-inflammatory hyperpigmentation.

Keywords: cosmetics; dermatology; epidermal growth factor; wound.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

FIGURE 1
FIGURE 1
Schematic view of intracellular signalling pathways involved in rhEGF function
FIGURE 2
FIGURE 2
(A) Clinical photographs of a chronic and recalcitrant traumatic wound in a 35‐year‐old female before, and (B) after two weeks of treatment with rhEGF ointment. (C) Clinical photographs of a traumatic abrasion wound in a 62‐year‐old male before, and (D) after three days of treatment with rhEGF ointment

References

    1. Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new‐born animal. J Biol Chem. 1962;237:1555‐1562. - PubMed
    1. Wenczak BA, Lynch JB, Nanney LB. Epidermal growth factor receptor distribution in burn wounds. Implications for growth factor‐mediated repair. J Clin Invest. 1992;90(6):2392‐2401. - PMC - PubMed
    1. Yang S, Geng Z, Ma K, Sun X, Fu X. Efficacy of topical recombinant human epidermal growth factor for treatment of diabetic foot ulcer: a systematic review and meta‐analysis. Int J Low Extrem Wounds. 2016;15(2):120‐125. - PubMed
    1. Dogan S, Demirer S, Kepenekci I, et al. Epidermal growth factor‐containing wound closure enhances wound healing in non‐diabetic and diabetic rats. Int Wound J. 2009;6(2):107‐115. - PMC - PubMed
    1. Krishnamurthy R, Manning MC. The stability factor: importance in formulation development. Curr Pharm Biotechnol. 2002;3(4):361‐371. - PubMed

Substances